Wilms Tumor vs Neuroblastoma: How to Tell Them Apart

Wilms tumor and neuroblastoma are the two most common solid abdominal tumors in children, yet they arise from entirely different tissues, behave in distinct ways, and require different treatment strategies. Wilms tumor (also called nephroblastoma) grows from embryonic kidney cells, while neuroblastoma develops from nerve tissue in the sympathetic nervous system. Both typically appear as large abdominal masses in young children, which is why they are so often compared, but the similarities are mostly superficial. Understanding where they diverge matters for diagnosis, treatment decisions, and what families can expect.

Where Each Tumor Comes From

Wilms tumor is a cancer of the kidney. It originates from cells that were supposed to mature into normal kidney tissue during fetal development but instead kept growing abnormally. Because of this, the tumor is almost always found within the kidney itself, typically pushing outward as a well-defined mass. On imaging, it tends to look like a ball sitting inside or distorting the kidney, with relatively clear borders.

Neuroblastoma comes from a completely different cell lineage. It arises from neural crest cells, the precursors to the sympathetic nervous system. That means it can pop up anywhere along the sympathetic nerve chain: the adrenal glands (sitting on top of the kidneys), the chest, the neck, or the pelvis. When it appears in the abdomen, it typically grows from the adrenal gland or the nerve tissue running alongside the spine. On CT scans, neuroblastomas tend to be poorly defined, heterogeneous masses that can extend across the midline of the body and invade adjacent body cavities, unlike the more contained appearance of Wilms tumor.¹

This difference in origin is the single most important distinction. Wilms tumor is always a kidney tumor. Neuroblastoma is a nerve-tissue tumor that happens to show up in the abdomen often enough to be confused with a kidney mass, but it can appear in places a kidney cancer never would.

Age and Who Gets Them

Both tumors strike young children, but their age peaks differ. Wilms tumor is most commonly diagnosed between ages three and four, with the vast majority of cases appearing before age five. Neuroblastoma tends to present even earlier, with a median age at diagnosis around 18 months, though it can occur in older children and, rarely, in adolescents or adults.

Demographic patterns also differ. Data from a large U.S. analysis found that Black non-Hispanic children made up about 18% of Wilms tumor cases but only about 11% of neuroblastoma cases, while White non-Hispanic children accounted for roughly 59% of Wilms tumor and 65% of neuroblastoma.² Racial and socioeconomic factors also affect survival outcomes for both cancers, though in sometimes surprising ways: the same study found that higher socioeconomic-status scores were actually associated with worse survival for both Wilms tumor and neuroblastoma, a counterintuitive finding that likely reflects the complexities of how social determinants interact with tumor biology and treatment access. Separately, Asian and Pacific Islander children have been found to have a higher risk of death from both neuroblastoma and Wilms tumor compared to White children.³

How They Are Discovered

Parents often notice the same thing with both tumors: a firm, painless lump in the child’s belly. A caregiver may feel the mass during a bath, or a pediatrician may detect it during a routine exam. Because both cancers can grow quite large before causing symptoms, the initial presentation can look strikingly similar.

Where they diverge is in the accompanying signs. Wilms tumor is classically associated with blood in the urine and high blood pressure, since the mass compresses or invades kidney tissue. Neuroblastoma, by contrast, can produce a wider array of unusual symptoms because nerve-tissue tumors secrete catecholamines (the same family of chemicals as adrenaline). Children with neuroblastoma may have episodes of sweating, flushing, or diarrhea. In some cases, neuroblastoma triggers a distinctive condition called opsoclonus-myoclonus syndrome, in which the child develops jerky, uncontrollable eye movements and muscle twitching. This paraneoplastic syndrome is essentially unique to neuroblastoma and does not occur with Wilms tumor.

Neuroblastoma can also present with a set of symptoms called Horner syndrome (a drooping eyelid, constricted pupil, and decreased sweating on one side of the face) when the tumor involves the sympathetic nerves in the neck or upper chest. A child with Horner syndrome would never be suspected of having Wilms tumor, so that presentation immediately narrows the diagnosis.

The Genetic Landscape

Despite both being embryonal tumors of childhood, Wilms tumor and neuroblastoma have almost entirely non-overlapping genetic drivers.

Wilms tumor is genetically heterogeneous. The best-known gene involved is WT1, a tumor suppressor on chromosome 11p13 that encodes a protein critical for normal kidney and genital development. When WT1 is inactivated in the germline, children can develop not only Wilms tumor but also severe abnormalities of the kidneys and reproductive organs.⁴ However, WT1 mutations account for only about 20% of Wilms tumors. A second gene, WTX, is mutated at a similar rate. Even combining WT1, WTX, and a third gene called CTNNB1, known mutations explain only about a third of all Wilms tumors, meaning the genetic basis of the majority remains unclear.⁵

Neuroblastoma’s genetics center on different players. The oncogene MYCN is the most clinically important: when extra copies of MYCN are present in the tumor (a phenomenon called amplification), the cancer tends to be aggressive, fast-growing, and harder to treat. Alongside MYCN, the ALK gene (anaplastic lymphoma kinase) has emerged as a key target. ALK is altered by mutations in roughly 14% of high-risk neuroblastoma cases and is an attractive therapeutic target because the protein is barely expressed in healthy tissue after birth.⁶ In a large European high-risk trial, ALK amplification was found in about 4.5% of cases and was nearly always accompanied by MYCN amplification. Children with ALK amplification had a five-year overall survival of just 28%, compared with 51% for those without it.⁷ The cooperation between MYCN amplification and ALK activation appears to drive tumor formation by blocking the normal wave of cell death that would otherwise eliminate overgrown nerve-cell precursors during development.⁸

One curious genetic footnote: although Wilms tumor and neuroblastoma are driven by different genes, a handful of families have been reported in which related individuals developed one or both tumors. In one study describing nine such families, the affected children were otherwise healthy and lacked any known genetic syndrome, suggesting a rare, still-unidentified genetic susceptibility that predisposes to both cancers.⁹

Where They Spread

The metastatic patterns of these two tumors are almost mirror images. Wilms tumor spreads through the blood most commonly to the lungs, with around 80% of patients who have metastatic Wilms tumor at diagnosis showing lung involvement.¹⁰ Liver and, less commonly, bone are also sites of Wilms tumor spread, but the lungs dominate. Neuroblastoma, conversely, favors bone and bone marrow as its primary metastatic sites, with liver involvement also common. Lung metastases in neuroblastoma are distinctly uncommon and, when present, tend to signal a particularly poor prognosis.¹¹

This difference has practical implications. A child with a suspicious abdominal mass and bone pain or bone-marrow involvement is much more likely to have neuroblastoma. A child with the same mass plus lung nodules on a chest X-ray is more likely to have Wilms tumor. These clues help radiologists and oncologists narrow the diagnosis even before a biopsy.

Treatment Philosophy

Surgery, chemotherapy, and radiation all play roles in both cancers, but the sequencing and emphasis differ.

For Wilms tumor, two major treatment philosophies exist in the world. In North America, the Children’s Oncology Group (COG) approach generally favors upfront surgery (removing the affected kidney) before any chemotherapy, so that the pathology of the untreated tumor can guide subsequent therapy. In Europe, the SIOP (International Society of Paediatric Oncology) approach starts with chemotherapy before surgery, aiming to shrink the tumor and make the operation safer.¹² Both strategies produce excellent results. The staging systems differ accordingly: the COG system relies on pathology from the primary surgery, while the SIOP system stages the tumor after preoperative chemotherapy.¹³ Both tumors have unique staging systems that depend heavily on imaging findings.¹⁴

Neuroblastoma treatment is more stratified by risk category. Low-risk neuroblastoma may need only surgery or, in some cases, observation alone. High-risk neuroblastoma requires an intensive combination of chemotherapy, surgery, radiation, and newer therapies. One of the most significant advances in neuroblastoma treatment has been immunotherapy targeting GD2, a molecule found on the surface of neuroblastoma cells. Anti-GD2 antibodies have improved survival in children who achieve remission and are now increasingly used even for relapsed or treatment-resistant disease.¹⁵ Wilms tumor, on the other hand, has not seen a comparable immunotherapy breakthrough, largely because the tumor does not present as convenient a surface target.

Survival Differences

Wilms tumor is one of the great success stories of pediatric oncology. Across European population-based data, three-year overall survival sits at about 95%, with stage I patients surviving at 99%.¹⁶ Even children with stage IV (metastatic) Wilms tumor have a three-year survival around 87%, a remarkably narrow gap between early and advanced disease compared with most cancers.

Neuroblastoma is a more uneven story. Overall three-year survival in the same European dataset was about 83%, but this average masks enormous variation. Low-risk neuroblastoma, particularly the kind found in infants, can have survival rates well above 90%, and some tumors even regress on their own without treatment. High-risk neuroblastoma, however, remains one of the most lethal pediatric cancers, with five-year survival figures for certain subgroups dipping below 30%, as seen in children whose tumors carry ALK amplification.¹⁷ In short, Wilms tumor is more consistently curable, while neuroblastoma splits into a bimodal distribution where some children do extremely well and others face a very difficult road.

Spontaneous Regression and the Screening Paradox

One of the most fascinating features of neuroblastoma, and one that has no parallel in Wilms tumor, is its capacity for spontaneous regression. Some neuroblastomas, particularly those diagnosed in infants under one year of age, can shrink and disappear entirely without any treatment. The biology behind this is still not fully understood, but it appears linked to the tumor’s stage of cellular maturation: certain neuroblastomas retain enough of their developmental programming to undergo the same cell death that normal nerve precursors would experience during fetal development.

This phenomenon created a major public-health conundrum. In the 1980s and 1990s, Japan and parts of Canada launched mass screening programs that tested infants’ urine for catecholamines, the chemical byproducts of neuroblastoma. The programs successfully found more neuroblastomas, but they did not reduce death rates. A landmark study from Quebec found no reduction in neuroblastoma mortality compared to unscreened populations across multiple control groups.¹⁸ Japan halted its screening program in 2003, and subsequent analysis confirmed that the incidence of diagnosed neuroblastoma dropped sharply after screening stopped, while the mortality rate did not change at all, strongly suggesting the program had been catching tumors that would have disappeared on their own.¹⁹ The screening experience became a textbook example of overdiagnosis in cancer medicine.

Wilms tumor does not spontaneously regress, and no comparable screening program has been attempted. The closest analogy is surveillance ultrasound for children with known genetic syndromes that predispose to Wilms tumor, such as Beckwith-Wiedemann syndrome or WAGR syndrome, but that is targeted monitoring of high-risk children rather than population-wide screening.

Living After Treatment

Surviving childhood cancer is the beginning of another chapter rather than the end of the story. Both Wilms tumor and neuroblastoma survivors face long-term consequences from the treatments that saved their lives, particularly if those treatments included radiation to the abdomen.

A systematic review examining late effects after upper abdominal radiation in Wilms tumor and neuroblastoma survivors found strong evidence for increased rates of metabolic syndrome, diabetes, and functional loss of the spleen. There was moderate evidence for elevated risk of second cancers, particularly kidney and colorectal carcinomas, and for chronic kidney disease.²⁰ These shared risks reflect the overlap in treatment (both may receive abdominal radiation) rather than any similarity in the underlying cancers.

Quality-of-life data paint a nuanced picture. A study comparing adult survivors of childhood Wilms tumor and neuroblastoma found no significant difference between the two groups on any physical or mental health measure. Both groups reported physical functioning comparable to the general population. However, both scored significantly below population norms on mental health scales, with average mental-health summary scores around 42 on a scale where 50 represents the population mean.²¹ The emotional burden of having had cancer as a child, combined with the ongoing vigilance for late effects, appears to weigh on survivors regardless of which tumor they had.

When the Two Tumors Mimic Each Other

Despite all their differences, there are clinical scenarios in which neuroblastoma and Wilms tumor can look nearly identical. A neuroblastoma arising from the adrenal gland can encase and distort the kidney so thoroughly that, on initial imaging, it appears to be a kidney tumor. Both cancers can extend a blood clot (thrombus) into the large veins draining toward the heart, a finding more classically associated with Wilms tumor but occasionally seen in neuroblastoma.²² In rare cases, even experienced radiologists cannot confidently distinguish the two on imaging alone.

When the diagnosis is uncertain, a few additional tests help sort things out. Neuroblastoma usually produces elevated urinary catecholamines (measured as vanillylmandelic acid and homovanillic acid), which Wilms tumor does not. A bone-marrow biopsy showing tumor cells strongly favors neuroblastoma. Certain imaging patterns, such as calcification scattered throughout the mass (common in neuroblastoma) versus a mass clearly arising from within the kidney substance (favoring Wilms tumor), can also tip the balance. In the COG approach, where upfront surgery is standard for Wilms tumor, an incorrect preoperative diagnosis could mean the wrong operation, so getting the distinction right matters.

The rarity of diagnostic overlap should be reassuring: in the vast majority of cases, the child’s age, tumor location, imaging characteristics, and basic lab tests make the diagnosis clear long before a pathologist examines the tissue. But for the small number of ambiguous cases, awareness that these two tumors can masquerade as each other remains an important part of pediatric oncology training.